Product Description
Mechanisms of Action: Radiotherapy Radioactive Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Steba Biotech
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2006-001530-40 |
2006-001530-40 | P2 |
Terminated |
Prostate Cancer |
2008-10-17 |
2022-03-12 |
Treatments |
|
NCT00305929 |
Repeat Procedure | P2 |
Completed |
Prostate Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00308919 |
HEC/WST03 658 N/WST 2.08 | P2 |
Completed |
Prostate Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00312442 |
HEC/WST0512 66N/WST 2.21 | P3 |
Terminated |
Prostate Cancer |
2008-07-01 |
2019-03-21 |
Treatments |